Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 149Breast Neoplasms 87Colorectal Neoplasms 64Neoplasms 53Pancreatic Neoplasms 52Lung Neoplasms 49Neoplasm Metastasis 45Stomach Neoplasms 43Ovarian Neoplasms 42Rectal Neoplasms 41Esophageal Squamous Cell Carcinoma 34Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 30Head and Neck Neoplasms 30Leukemia, Myeloid, Acute 28Recurrence 24Triple Negative Breast Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Glioblastoma 21Uterine Cervical Neoplasms 20Small Cell Lung Carcinoma 20Nasopharyngeal Carcinoma 20Fallopian Tube Neoplasms 19Lymphoma, Non-Hodgkin 18Lymphoma 18Colonic Neoplasms 17Prostatic Neoplasms 16Leukemia 15Carcinoma, Ovarian Epithelial 15Melanoma 14

Interventions

tanespimycin 2pembrolizumab 2parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2Capecitabine 2zanidatamab 1tislelizumab 1spartalizumab 1sitravatinib 1repaglinide 1pemigatinib 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1drospirenone 1cabiralizumab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1HMPL-013 1Gemcitabine 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Malignancies × Drug Therapy × Clear all
NCT06468098 2024-07-18

A Study of IBI363 in Subjects With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Recruiting
556 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡